In:
Clinical Pharmacology & Therapeutics, Wiley, Vol. 111, No. 3 ( 2022-03), p. 559-571
Abstract:
Male patients with coronavirus disease 2019 (COVID‐19) fare much worse than female patients in COVID‐19 severity and mortality according to data from several studies. Because of this sex disparity, researchers hypothesize that the use of exogenous sex hormone therapy and sex hormone receptor modulators might provide therapeutic potential for patients with COVID‐19. Repurposing approved drugs or drug candidates at late‐stage clinical development could expedite COVID‐19 therapy development because their clinical formulation, routes of administration, dosing regimen, clinical pharmacology, and potential adverse events have already been established or characterized in humans. A number of exogenous sex hormones and sex hormone receptor modulators are currently or will be under clinical investigation for COVID‐19 therapy. In this review, we discuss the rationale for exogenous sex hormones and sex hormone receptor modulators in COVID‐19 treatment, summarize ongoing and planned clinical trials, and discuss some of the clinical pharmacology considerations on clinical study design. To inform clinical study design and facilitate the clinical development of exogenous sex hormones and sex hormone receptor modulators for COVID‐19 therapy, clinical investigators should pay attention to clinical pharmacology factors, such as dosing regimen, special populations (i.e., geriatrics, pregnancy, lactation, and renal/hepatic impairment), and drug interactions.
Type of Medium:
Online Resource
ISSN:
0009-9236
,
1532-6535
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2040184-X
SSG:
15,3
Bookmarklink
